General MedicationsTRANSDERMALStandard
EVAMIST
ESTRADIOL
Standard Dose
1.53MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview EVAMIST is listed in Drugs@FDA under application 022014 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ESTRADIOL Form and strength SPRAY;TRANSDERMAL - 1.53MG/SPRAY Sponsor PADAGIS US Submission history Latest submission status date: 2024-02-15 00:00:00.
Structured Monograph
Clinical summary
Approval overview EVAMIST is listed in Drugs@FDA under application 022014 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ESTRADIOL Form and strength SPRAY;TRANSDERMAL - 1.53MG/SPRAY Sponsor PADAGIS US Submission history Latest submission status date: 2024-02-15 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.